Immunic (IMUX) EBIT (2013 - 2026)

Immunic has disclosed EBIT across 14 years of filings, most recently posting -$33.2 million for Q1 2026.

• EBIT for Q1 2026 came in at -$33.2 million, down 23.9% year-over-year; the trailing twelve-month figure through Mar 2026 was -$109.6 million (down 8.56% YoY), and the FY2025 annual result was -$103.2 million, down 5.28% from the prior year.
• EBIT came in at -$33.2 million for Q1 2026 at Immunic, down from -$23.3 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$20.1 million in Q3 2022 to a low of -$57.3 million in Q4 2022.
• The 5-year median for EBIT is -$25.0 million (2023), against an average of -$26.7 million.
• Across the five-year window, EBIT tumbled 163.92% in 2022 and jumped 59.21% in 2023, its largest moves.
• Immunic's EBIT stood at -$57.3 million in 2022, then surged by 59.21% to -$23.4 million in 2023, then fell by 9.62% to -$25.6 million in 2024, then increased by 8.99% to -$23.3 million in 2025, then slumped by 42.47% to -$33.2 million in 2026.
• The last three EBIT figures came in at -$33.2 million (Q1 2026), -$23.3 million (Q4 2025), and -$26.0 million (Q3 2025), per Business Quant data.